Synexus expands in South Africa

By Nick Taylor

- Last updated on GMT

Related tags South africa Clinical trial

Synexus is to more than double its clinical trial capacity in South Africa, in response to a successful couple of years in the nation.

The increased capacity will come from the building of two purpose designed sites in Mamelodi and Soshanguwe, as well as an expansion of the existing facilities in Pretoria.

Synexus expanded in the South African market in 2006 through the acquisition of CRC SA and now regards the country as one of its most successful sites.

Dr Sanet Aspinall, South Africa country manager, said: "We are able to carry out a wide variety of clinical studies involving both outpatients and inpatients through our own hub sites, our 36 bed unit as well as affiliated general practitioner and hospital based sites​.

Since 2006 we have been able to increase turnover by more than 60 per cent as being part of a global clinical trials organisation has given us the opportunity to be involved in many more global studies​."

The Pretoria facility is being expanded into the adjoining building, creating a 562 sq m outpatient site for clinical trials. Negations are underway to establish the locations of the new sites, with Synexus hoping to have the facilities completed by March 2009.

Synexus’ current operations in South Africa cover paediatric vaccines, osteoporosis, women's health and post operative pain, across Phases II and III. Upon completion of the expansion Synexus will employ 25 clinically trained staff in South Africa.

From these facilities Synexus will continue to recruit for and run clinical trials on behalf of pharmaceutical and biotech companies.

Benefits of South Africa

Synexus has operations in the UK, Poland, Hungary, Bulgaria, India and South Africa, holding the latter in particularly high regard. Michael Fort, Synexus’ CEO, attributed this to the high number of patients it has recruited in the country and the quality of clinical trials performed.

Recruiting in South Africa is relatively quick as the population is genetically diverse and treatment naïve. The country also has a stringent regulatory process to ensure patient safety.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more